



UNIVERSITY OF LEEDS

This is a repository copy of *EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/155874/>

Version: Supplemental Material

Article:

Smolen, JS, Landewé, RB, Bijlsma, JWJ et al. (44 more authors) (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Annals of the Rheumatic Diseases*. ISSN 0003-4967

<https://doi.org/10.1136/annrheumdis-2019-216655>

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This manuscript version is made available under the CC BY-NC 4.0 license <https://creativecommons.org/licenses/by-nc/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here:
<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table 1. Glossary and definitions (after¹)

Term	Definition	
Poor prognostic factors	<ul style="list-style-type: none"> • Persistently moderate or high disease activity (after csDMARD therapy) according to composite measures despite csDMARD therapy • High acute phase reactant levels • High swollen joint count • Presence of RF and/or ACPA, especially at high levels • Presence of early erosions • Failure of 2 or more csDMARDs 	
Low dose glucocorticoids	<ul style="list-style-type: none"> • ≤ 7.5mg/day (prednisone equivalent) 	
Tapering	<ul style="list-style-type: none"> • Reduction of drug dose or increase of application interval • May include cessation (tapering to 0), but then only after slow reduction 	
Cessation, stopping	Stopping of a particular drug	
Disease activity states		
Remission	ACR-EULAR remission definition (Boolean or index-based)	
Low disease activity	Low disease activity state according to any of the validated composite disease activity measures	
Moderate, high disease activity	Respective disease activity state according to any of the validated composite disease activity measures	
DMARD nomenclature		
Synthetic DMARDs (sDMARDs)	<ul style="list-style-type: none"> • Conventional synthetic DMARDs (csDMARDs) 	E.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine
	<ul style="list-style-type: none"> • Targeted synthetic DMARDs (tsDMARDs) 	E.g. baricitinib, tofacitinib
Biological DMARDs (bDMARDs)	<ul style="list-style-type: none"> • Biological originator DMARDs (boDMARDs) 	TNFi: adalimumab, certolizumab, etanercept, golimumab, infliximab; IL-6Ri: sarilumab, tocilizumab; Co-stimulation-i: abatacept; anti-B-cell (CD20): rituximab
	<ul style="list-style-type: none"> • Biosimilar DMARDs (bsDMARDs), currently for: 	adalimumab, etanercept, infliximab, rituximab.

ACPA, anti-citrullinated protein antibody; ACR, American College of Rheumatology; DMARDs, disease-modifying antirheumatic drugs; EULAR, European League Against Rheumatism; RF, rheumatoid factor.

(1) Smolen JS, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* 2017; 76:960-977.